GMTX vs. OGN, IONS, BBIO, CYTK, MDGL, APLS, ALPN, NUVL, ALKS, and PRGO
Should you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Madrigal Pharmaceuticals (MDGL), Apellis Pharmaceuticals (APLS), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Gemini Therapeutics (NASDAQ:GMTX) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
Gemini Therapeutics received 3 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 63.33% of users gave Gemini Therapeutics an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 1.4% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Organon & Co. has a net margin of 16.50% compared to Gemini Therapeutics' net margin of 0.00%. Gemini Therapeutics' return on equity of -38.78% beat Organon & Co.'s return on equity.
Organon & Co. has a consensus price target of $22.60, indicating a potential upside of 5.95%. Given Organon & Co.'s higher possible upside, analysts clearly believe Organon & Co. is more favorable than Gemini Therapeutics.
In the previous week, Organon & Co. had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for Organon & Co. and 0 mentions for Gemini Therapeutics. Organon & Co.'s average media sentiment score of 1.39 beat Gemini Therapeutics' score of 0.00 indicating that Organon & Co. is being referred to more favorably in the news media.
Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
Organon & Co. has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Summary
Organon & Co. beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Gemini Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemini Therapeutics Competitors List
Related Companies and Tools
